Table 1 Patient characteristics
Characteristics | (N = 17 patients) |
|---|---|
Sex | |
Male - no. (%) | 9 (53) |
Female - no. (%) | 8 (47) |
Age | |
N | 17 |
Mean (Standard deviation) | 67,4 (8.5) |
Median [min - max] | 69 [49–81] |
Primary site | |
Colon - no. (%) | 13 (76.5) |
Rectal - no. (%) | 4 (23.5) |
Sidedness | |
Left side (colon and rectum) - no. (%) | 13 (76.5) |
Right side - no. (%) | 4 (23.5) |
Median duration of disease before inclusion — mo (range) | 38 (8-50) |
No. of metastatic sites | |
1 or 2 - no. (%) | 11 (64.7) |
≥ 3 - no. (%) | 6 (35.3) |
RAS Mutational status | |
Mutated - no. (%) | 13 (76.5) |
Wild-type - no. (%) | 4 (23.5) |
MMR status | |
dMMR - no. (%) | 0 (0) |
pMMR - no. (%) | 17 (100) |
No. of previous treatments for metastatic disease | |
1 - no. (%) | 1 (5.9) |
2 - no. (%) | 7 (41.2) |
≥3 - no. (%) | 9 (52.9) |
ECOG performance-status score | |
0 - no. (%) | 8 (47) |
1 - no. (%) | 9 (53) |
Previous treatment received for metastatic disease | |
Fluoropyrimidine - no. (%) | 17 (100) |
Irinotecan - no. (%) | 17 (100) |
Oxaliplatin - no. (%) | 17 (100) |
Anti-VEGF moonoclonal antibody - no. (%) | 17 (100) |
Anti-EGFR monoclonal antibody - no. (%) | 4 (23.5) |
Regorafenib - no. (%) | 3 (17.6) |
